论文部分内容阅读
目的观察依达拉奉对急性脑梗死患者血清神经元特异性烯醇化酶(NSE)、S100蛋白水平的影响。方法选择急性脑梗死患者70例,随机分为治疗组及对照组,对照组常规用疏血通注射液6mL+生理盐水250mL静脉滴注,治疗组为对照组加用依达拉奉30mg+生理盐水250mL静脉滴注,1次/d,连续治疗10d。分别于治疗前及治疗10d后各抽取患者肘静脉血3mL,1000r/min离心取上清液检测NSE、S100蛋白水平,对所测结果进行统计学分析。结果对照组、治疗组治疗前NSE水平、S100B蛋白二者间无显著性差异(P>0.05)。治疗10d后二者较治疗前均有下降,治疗组低于对照组(P<0.05)。动态观察31例发病36 h入院的患者,对照组随着发病时间的延长,血清NSES100蛋白含量逐渐升高,其中NSE于发病后第72h达峰值,S100蛋白于发病后第120h达峰值,以后逐渐下降。而治疗组发病后72、120、168h均低于对照组(P<0.05)。结论依达拉奉能够减轻脑缺血及再灌注的损伤,起到保护神经细胞的作用。
Objective To observe the effect of edaravone on serum neuron specific enolase (NSE) and S100 protein in patients with acute cerebral infarction. Methods Seventy patients with acute cerebral infarction were randomly divided into treatment group and control group. The control group was given intravenous infusion of Shuxuetong injection 6 mL + normal saline 250 mL, and the control group was treated with edaravone 30 mg + normal saline 250 mL Intravenous infusion, 1 time / d, continuous treatment 10d. Respectively before treatment and after treatment 10d elbow venous blood samples were drawn 3mL, 1000r / min centrifuged supernatant NSE, S100 protein levels were measured, the results were statistically analyzed. Results There was no significant difference in NSE level and S100B protein between the control group and the treatment group before treatment (P> 0.05). After treatment for 10d, both of them decreased compared with that before treatment, and the treatment group was lower than the control group (P <0.05). Dynamic observation of 31 patients admitted to hospital at 36 h onset, the control group with the onset of time, serum NSES100 protein levels gradually increased, of which NSE peaked at 72h after onset, S100 protein peaked at 120h after onset, and gradually decline. The treatment group 72,120,168 h after onset are lower than the control group (P <0.05). Conclusion Edaravone can reduce the damage of cerebral ischemia and reperfusion and play the role of protecting nerve cells.